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Randomized clinical trials: How will results
influence clinical practice in the management of
symptomatic and asymptomatic extracranial
carotid occlusive disease?
Robert W. Hobson II, MD, Newark, NJ
Evaluation of the efficacy of carotid endarterectomy and stenting requires careful consideration of clinical trial
methodology as applied to the primary clinical end points of the specific trial. Although publication of observational data
including registries is helpful in selecting options for further study, these reports are not considered replacements for the
randomized clinical trial. This article reviews methodology and results of registries and randomized clinical trials.
Pending publication of larger clinical trials on the management of symptomatic and asymptomatic carotid stenosis within
the next 1 to 3 years, carotid endarterectomy remains the preferred technique for cerebral revascularization. The only
exceptions to this recommendation come from higher risk categories of patients; however, their identification is
frequently difficult and controversial. ( J Vasc Surg 2007;45:158A-163A.)Carotid endarterectomy (CEA) stands as an approved
method for revascularization of symptomatic and asymp-
tomatic patients with extracranial carotid occlusive dis-
ease.1-6 Enthusiasm has grown for carotid artery stenting
(CAS) as a less invasive procedure,7-12 but the lack of
efficacy data compared with CEA in better-risk patients has
limited acceptance of the technique. Although CAS has
been recommended in specialized subsets of patients,13
such as restenosis after CEA, radiation-induced carotid
stenosis, anatomically high lesions above the second cervi-
cal vertebra, and in higher-risk patients, its use in better-risk
patients has generally been reserved for patients enrolled in
clinical trials. The purpose of this review is to update the
results and status of relevant clinical trials and to estimate
when the presentation and publication of additional more
definitive trial data may be anticipated.
CLINICAL TRIAL METHODOLOGY
In evidence-based analyses, the roles for randomized
clinical trials (RCTs) and observational studies have been
debated extensively. RCTs are used for efficacy analyses
when anticipated differences in treatment modalities are
not great and each patient’s treatment is chosen by ran-
domization to preclude the risk of selection bias and other
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158Adifferences that may not be related to the treatment it-
self.14-16 Investigators define a population for study
through the trial’s inclusion and exclusion criteria and
select experienced clinicians to perform the treatments.
RCTs can have limitations in terms of generalizability.
An example of this issue would be the recommended
management for octogenarians with extracranial carotid
occlusive disease. The North American Symptomatic Ca-
rotid endarterectomy Trial (NASCET)1 and Asymptomatic
Carotid Atherosclerosis Study (ACAS)5 investigators ex-
cluded patients in that age group, and definitive recom-
mendations are not available. If the selected clinicians are
highly skilled, the study results from an RCT may also be
criticized as not being applicable to all centers.
Observational studies are useful to evaluate effective-
ness and can supplement the results of RCTs.14 These
studies evaluate effectiveness in the application of the treat-
ments in routine practice. Observational studies are not
considered replacements for RCTs in terms of providing
level I evidence and class A clinical recommendations14 for
the management of symptomatic and asymptomatic ex-
tracranial carotid occlusive disease. As described by Califf,17
data from RCTs are used to devise guidelines, measure
performance, and conduct further outcome analyses (Fig 1).
Consequently, these data have significant influence on the
practice patterns of all clinicians compared with the more
limited applications for observational study data.
Of additional importance is the analytic method used
by the authors of a clinical trial. In many trials,1,5,18 the
results are presented as a superiority analysis that allows the
investigators to conclude whether one treatment is better
or worse than the other treatment. The noninferiority or
equivalency trial19 is unable to make the same conclusions
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or may not be inferior to or equivalent to the established
treatment.
In a superiority trial, the investigators’ proposal gener-
ally leads to rejection of the null hypothesis and a demon-
stration of differences between the two interventions. In
the noninferiority trial, the investigators are comparing an
innovative new treatment with a gold standard within a
noninferiority interval or delta, which has been evaluated
and recommended by the investigators for the primary
outcome. The noninferiority trial is frequently used to
assess a new therapy against a gold standard in which the
new therapy may be considered safer or less invasive.
As emphasized by Gotzsche,19 the confusing part of a
noninferiority trial is the proper selection of the delta or
difference in planning the trial, which then impacts the
calculations of sample sizes. In one of his examples, which is
comparable to issues related to CEA, if the estimated event
rate was 3.1% but a delta of 2% were chosen, it would be
arguably too large and may lead to a report in which the
new treatment is “at least as effective” as the gold standard,
which may be unwarranted unless the entire confidence
interval lies outside the noninferiority interval correspond-
ing to a P  .05 in a test of superiority. Unfortunately, the
delta can also be modified if the early analysis demonstrated
that the treatment was inferior; with this change in delta, an
altered conclusion can be made that the new treatment was
not inferior and that the sample size was sufficient.
It is important to recall that a noninferiority trial can
only demonstrate that the new intervention is not worse
than the comparable gold standard by more than a pre-
specified amount or delta. A noninferiority trial’s publica-
tion should include definitions and justification of the
noninferiority equivalency margin or delta, calculations of
the sample size taking this margin into account, presenta-
tion of both intention to treat and protocol analysis, and
provide confidence intervals for the results. In their ab-
Fig. The cycle of clinical therapeutics. (With permission from
Califf RM. Translating clinical trials into practice. Heart Inst J
2006;33:192-6.)sence, the conclusions of a noninferiority trial are suspect.20CLINICAL PROTOCOLS AND RESULTS
This report is intended to review clinical trials that
compare the results of CAS and CEA. Many nonrandom-
ized registry results were published in a recent review by
Naylor.21 Stroke, death, and myocardial infarction rates at
30 days postprocedure were 3.8% to 8.5%, and 30-day
stroke and death rates alone were 3.6% to 6.9%. These
registries were not controlled, however, and assignment of
patients may have been related to clinical biases of the
treating physicians. Although they do reflect information
about the effectiveness of treatment in the referenced insti-
tutions, these data will not replace information from RCTs
and will not result in level I evidence or class A clinical
recommendations.
A comparison of RCTs (200 patients) in symptom-
atic and asymptomatic patients will be presented. Data
from four randomized trials among symptomatic patients
and one with predominantly asymptomatic patients are
summarized in Table I. Data on larger (1500 patients)
RCTs, some of which will be completed within the next 1
to 3 years, are summarized in Table II.
The Wallstent trial22 was conducted in the early 1990s
using a Wallstent (Boston Scientific, Natick Mass) without
cerebral protection and demonstrated significant differ-
ences for symptomatic patients with 60% to 99% stenoses.
Stroke and death rates at the 30-day postprocedure interval
were reported as 12.1% for CAS and 4.5% for CEA, which
favored CEA.However, absence of cerebral protectionmay
have contributed to the unacceptably high stroke and death
rate with CAS.
The Carotid and Vertebral Artery Transluminal Angio-
plasty Study (CAVATAS) trial23 randomized 500 symp-
tomatic patients with stenoses of 50% to 99%. Stents were
used in only 22% of the patients, however, and cerebral
protection was not available. The stroke and death rate at
30 days postprocedure was 9.9% for CEA and 10% for CAS,
and death or disabling strokes were observed in 5.9% of
CEA patients and 6.4% of CAS patients. Cranial nerve
palsies were recognized in 8.7% of CEA patients, and none
was observed with CAS. The evaluation of this study was
clouded, however, because the death and any stroke rate
was higher than anticipated and higher than the American
Heart Association’s recommendations for carotid endarter-
ectomy.24
More recent publications by the Stent-Supported Per-
cutaneous Angioplasty of the Carotid Artery versus Endar-
terectomy25 (SPACE) and Angioplasty in Patients with
Symptomatic Severe Carotid Stenosis (EVA-3S)26 investi-
gators have suggested a preference for CEA in symptomatic
patients. These differences were quite controversial in their
analyses, however. The SPACE trial25 randomized 1200
patients with stenoses of 50% to 99%. Stents were used
universally, and cerebral protection devices were used in
26% of the patients in SPACE. The SPACE investigators
reported 30-day stroke and death rates of 6.3% for CEA and
6.8% for CAS, which were not significantly different. As an
inferiority trial, however, randomization of patients was
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proven to be noninferior to CEA and possibly would not
have been proven according to the trial’s authors, even with
the recruitment of twice the sample size of 1200 patients.
The trial was, unfortunately, also abandoned because of
limited funding, but the investigators emphasized a result
that favored CEA over CAS.
The EVA-3S investigators26 randomized 527 symp-
tomatic patients with stenoses of 70% to 79%, and 73%were
treated with cerebral protection devices. These trialists
reported a 30-day death and any-stroke rate of 3.8% for
CEA and 9.5% for CAS, which was a significant (P  .05)
result favoring CEA. Two major flaws have been noted in
the trial, however. First, the 27% of patients who were not
treated with cerebral protection demonstrated a trend to-
ward poorer outcomes than in patients with cerebral pro-
tection, although the differences were not significant.
Second, the credentialing of interventionalists was also
a matter of some concern: some interventionalists gained
approval for participation in the trial by being proctored on
as few as two cases. The investigators then were permitted
to choose any one of five stents or seven cerebral protection
devices. Also, the number of patients randomized during
58 months at 30 centers26 resulted in an average of five
patients randomized per year per center. These procedures
were performed infrequently by interventionalists who may
not have been experienced or well credentialed.
Three of four RCTs with larger sample sizes of 1500
patients (Table II) among symptomatic and asymptomatic
Table I. Summary for published results from four random
predominately asymptomatic patients (CEA vs CAS)
WALLSTENT CAVA
Methodology
Year published 2001 200
No randomized
CEA 112 253
CAS 107 251
Stenosis range (%) 60-99 50-9
Stent used Wallstent 22% sten
CPD used (%) None available None av
30-day outcomes CEA/CAS (%) CEA/CA
Death
Death/ipsilateral stroke
Death/any stroke 4.5/2.1 9.9/1
Death/disabling stroke 5.9/6
Cranial nerve injury 8.7
Wound/access complications 4.00 6.7/1
CAVATAS, Carotid and Vertebral Artery Transluminal Angioplasty Study;
Endarterectomy; EVA-3S, Angioplasty in Patients with Symptomatic Seve
Patients at High Risk for Endarterectomy
Modified from Naylor RA. Chapter 4. In: Earnshaw JJ, Murie JA, editors. T
27-45, with permission.
*This trial was in predominately asymptomatic patients.
†Cordis, Miami Lakes, Florida.patients are scheduled for completion and publication ofdata within the next 1 to 3 years. These include the Carotid
Revascularization Endarterectomy vs. Stenting Trial
(CREST) in asymptomatic and symptomatic patients
(funded by National Institute of Neurological Disorders
and Stroke [NINDS], National Institutes of Health
[NIH]); the Asymptomatic Carotid Stenosis Trial II
(ACST I) in asymptomatic patients (funded by the Na-
tional Health Service, United Kingdom), the Asymptom-
atic Carotid Trial (ACT-1), funded by Abbott Vascular,
and the International Carotid Surgery Study (ICSS) in
symptomatic patients (funded by the Medical Research
Council, United Kingdom).
CREST. Stimulated by our clinical experience11,12,27-30
and other reference reports, the CREST investigators re-
ceived approval for funding from the NINDS, NIH, for a
trial to compare the efficacy of CEA and CAS in symptom-
atic patients with high-grade (70%) stenosis.18 The
threshold lesion for symptomatic patients27 was lowered to
50% stenosis, and asymptomatic patients with 70% ste-
noses by ultrasound were included in CREST after April
2005. However, recognizing that CAS was a relatively new
procedure at many sites, each participating center was
required to complete a credentialing phase to reassure
clinicians that the safety of these procedures had been
reviewed and established before approval for the random-
ized phase of the trial.
The lead-in or credentialing phase required the perfor-
mance of up to 20 interventional procedures using the
CREST study devices at each of more than 100 participat-
trials in symptomatic patient and one trial in
SPACE EVA-3S SAPPHIRE*
2006 2006 2004
595 263 221
605 264 117
50-99 70-99 80-99
Yes Yes Precise†
Variable types Variable types
e 26 73 Angioguard†
) CEA/CAS (%) CEA/CAS (%) CEA/CAS (%)
0.9/0.7
6.3/6.8
6.5/7.7 3.8/9.5 6.1/5.8
3.8/4.7
E, Stent-Supported Percutaneous Angioplasty of the Carotid Artery versus
rotid Stenosis; SAPPHIRE, Stenting and Angioplasty with Protection in
dence for vascular surgery. 2nd ed. Shrewbury, UK: tfm Pub, Ltd; 2007. p.ized
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domization of patients between the two treatments was
then approved. The primary outcome events for this clinical
trial include (1) any stroke, myocardial infarction, or death
during the 30-day perioperative or periprocedural period,
or (2) ipsilateral stroke 30 days.
End points are reviewed by an Adjudication Commit-
tee, blinded to the assigned treatment. Stroke will be
determined by a positive transient ischemic attack/stroke
questionnaire and NIH stroke scale as performed preoper-
atively and postoperatively and at 30 days by a study neu-
rologist. The diagnosis of postoperative or procedural myo-
cardial infarction is determined by the electrocardiography
and enzyme abnormalities.
Secondary goals include to (1) describe differential
efficacy of the two treatments in men and women, (2)
TABLE II. Methodology and contact details for the curr
Methodology ACT 1
Type of triala Noninferiority Eq
Multicenter Yes Ye
Recruiting country North America W
Treatment optionsb CAS vs CEA CA
Funding source Abbott Vascular NH
Number intended to be in trialc 1858 50
Randomization ratiosd CAS 3:CEA 1 CA
Randomization started? Yes No
Participant record reviewe Yes Ye
Proctoring/mentoring for CAS?f No No
Stenosis rangeg “Severe” “S
Stenosis measurement methodh NASCET NA
Ve
Stent used in study Xact Rapid Exchange CE
CPD
Obligatory/optional Obligatory Op
Type Emboshield CE
Dual antiplatelet therapy Yes Ye
End points at 30 days Death/stroke/MI De
30-d to 1-y
ipsilateral stroke
5-
Contact details dana.fletcher@abbott.
com
acs
ACT1, Asymptomatic Carotid Trial; ACST II; Asymptomatic Carotid Steno
TACIT, Trans Atlantic Carotid Interventional Trial; MI, myocardial infarct
Emboshield and Xact Rapid Exchange, Abbott, Abbott Park, Ill; Rx Accun
From Naylor RA. Where next after SPACE and EVA-3S: The good, the ba
aNoninferiority, equivalence, superiority.
bCarotid angioplasty (CAS), carotid endarterectomy (CEA), best medical t
cNumber of patients that power calculation deems necessary for trial compl
dRatio of CAS to CEA/BMT in trial.
eIs a track record review undertaken in order to select trial participants?
fDoes the trial allow for less experienced CAS practitioners to randomize pa
perform CAS independently within the trial?
gRange of stenoses being randomized.
hStenosis measurement method; ie, North American Symptomatic Carotid
iFood and Drug Administration (FDA) approved, Conformité Européen
European Directives.
jNational Health Service Research Health Technology Assessment program
kNational Institute of Neurological Disorders and Stroke.
lNote the slightly different stenosis thresholds depending upon whether imcontrast perioperative and procedural (30-day) morbidityand postprocedural mortality rates for the CEA and CAS
procedures, (3) estimate and contrast the restenosis rates
for the two procedures, (4) to identify subgroups of partic-
ipants at differential risk for the two procedures, and (5)
evaluate differences in health-related quality-of-life issues
and cost-effectiveness.
A differential gender-based efficacy assessment of CEA
and CAS is a secondary goal for CREST. In patients with
high-grade asymptomatic stenosis that were reported by
ACAS, CEA offered a 66% relative risk reduction in events
during a 5-year period for men but only a 17% reduction for
women.5 In NASCET, although no differential gender
effects were reported among symptomatic patients with
70% stenosis,1 men demonstrated greater benefit after
CEA than women for 50% to 69% stenoses.31 The causes
for these examples of differential efficacy between genders
andomized trials
CST II CREST TACIT
ence Superiority Superiority
Yes Yes
ide North America North America, Europe
CEA CAS vs CEA CAS vs BMT
D HTAj NINDSk To be determined
2500 2500
EA 1 CAS 1:CEA 1 CAS 1:BMT 1
Yes No
Yes Yes
No No
” 60%-99% angio 50%
70%-99% USl
T/ECST NASCET NASCET
data needed
rovedi Acculink FDA/CE approvedi
l Obligatory Obligatory
rovedi RX Accunet FDA/CE approvedi
Yes Yes
stroke/MI Death/stroke/MI Death/stroke/MI
ke
disabling)
“Late” ipsilateral
stroke
5-y stroke rate
Neurocognitive decline
ul.ac.uk www.umdnj.edu/
crestweb
www.sirfoundation.org/
misc/tacit.shtml
ial II; CREST, Carotid Revascularization Endarterectomy vs Stenting Trial;
idant Corporation, Indianapolis, Ind.
the ugly. Eur J Vasc Endovasc Surg 2007;33:44-47, with permission.
(BMT).
but be proctored by more experienced practitioners before being allowed to
terectomy Trial (NASCET), European Carotid Surgery Trial (ECST)
) mark indicates that the product meets the requirements of all relevant
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caused by their reported smaller arterial sizes and a greater
surgical morbidity.
Unfortunately, neither ACAS nor NASCET suspected
the possibility of a differential gender effect. However,
given the results of these two randomized clinical trials, a
requirement for a priori plans to evaluate the possibility of a
differential gender effect has become an important compo-
nent of CREST. Centers are being selected with a goal of
recruiting 40% women in the randomized sample of pa-
tients, which if achieved, will provide an 80% power to
answer this question.
Patients will be evaluated at baseline, at 24 hours after
the procedure, at 30 days, at 6 months, and thereafter at
6-month intervals. Baseline procedures will include a brief
medical history and physical examination, a risk-factor eval-
uation, and the results of a neurologic status questionnaire
will be evaluated by a neurologist. The sample size for the
study is approximately 2500 symptomatic patients, which
will be sufficient to detect a relative risk reduction at a
minimum of 25% to 30% between treatment groups. Lesser
differences would be considered sufficiently small to declare
the treatments equivalent.
An analysis of the lead-in CREST registry on 1246
patients was recently published32 and represents the largest
cohort of CAS patients with protocol-driven neurologic
examinations. The 30-day stroke and death rate was 3.9%
(5.6% for symptomatic patients and 3.4% for asymptomatic
patients). These rates are similar to those reported for CEA
in symptomatic patients.1 Despite inclusion of the higher-
risk octogenarians in the asymptomatic group, the stroke
and death rates approach the reported data from ACAS5
and are only moderately above the 3% limit recommended
by the American Heart Association consensus report.24
These data confirm clinical equipoise for the randomization
of patients between CAS and CEA.33 CREST has random-
ized 1584 patients (approximately 50% symptomatic) as of
February 1, 2007, and anticipates completion of patient
enrollment (n  2500) by mid-2008.
The Stenting and Angioplasty with Protection in Pa-
tients at High Risk for Endarterectomy (SAPPHIRE) in-
vestigators20 randomized 327 patients among 30 centers.
Two thirds of the sample were asymptomatic patients with
stenoses of 80% (Table I), and the rest were symptomatic
and had stenoses50%. These investigators were unable to
show any reduction in stroke and death rate with CAS
compared with CEA in symptomatic or asymptomatic pa-
tients. However, with the addition of myocardial infarc-
tion, some associated with enzyme changes only, investiga-
tors concluded that CAS was not inferior to CEA (P 
.047) for the study’s entire cohort of patients. One needs to
keep in mind the prerequisites recommended for a nonin-
feriority or equivalency trial,19 which these investigators
did not fulfill in their publication.20 As a consequence, the
results are not as decisive as clinicians require and are
restricted to high-risk patients only.
The extension of the prior CAVATAS23 trial to the
ICSS anticipates the randomization of 1500 to 1800 symp-tomatic patients. The trial’s design is similar to CREST but
does not specify the type of stent or cerebral protection to
be used. However, combined analyses of data will be ar-
ranged as the ICSS andCREST complete enrollments. This
will also apply to the soon to be initiated ACST II trial
which anticipates randomization of 5000 patients in cen-
ters originally selected for the ACST study.6
ACT-1 (sponsored by Abbott Vascular) investigators
will randomize asymptomatic patients in a ratio of one CEA
to three CAS procedures (personal communication by K
Rosenfield and J Matsumura, Co-Principal Investigators,
2006). The study initiated patient enrollment in 2006 and
has randomized 300 patients. No further plans or data
have been published by these investigators.30
The results of these trials should clarify indications in
symptomatic and asymptomatic patients of good risk com-
pared with the registries and prior randomization trials that
generally have used higher-risk patients. The goal of defin-
ing indication for CEA and CAS may also be achieved. It is
possible that specified lesions such a restenosis may be
better treated by CAS and heterogeneous ulcerated lesions
may be better treated with CEA. This may result in a
complementary relationship for CAS and CEA in the man-
agement of extracranial carotid occlusive disease.
Finally, the Trans Atlantic Carotid Interventional Trial
(TACIT) investigators are in the planning phase of a supe-
riority trial that anticipates recruitment of 2500 patients
(personal communication, B. Katzen, MD, Principal Inves-
tigator, 2007). Originally designed to randomize symp-
tomatic and asymptomatic subjects to one of three arms,
CEA vs CAS vs best medical therapy, this plan was recently
modified to randomize patients between CAS and best
medical therapy. Sponsors are being recruited and initiation
of the trial is anticipated this year.
CONCLUSIONS
For the immediate future, patients with symptomatic
and asymptomatic disease should be treated preferentially
with CEA rather than CAS. Clinicians also must be encour-
aged to participate in RCTs that involve better-risk pa-
tients. Until such time as more definitive data from larger
efficacy trials are available (Table II) to guide a change in
practice, the only exceptions to such a recommendation
must be based on each interventionalist’s experience for
specialized subsets of patients, such as restenosis after CEA,
anatomically high lesion, radiation-induced stenosis, or the
symptomatic high-risk patient group.
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